Tirzepatide vs. semaglutide head-to-head: trial differences, dose-response, and what the comparison actually supports

The mechanism difference

Semaglutide is a GLP-1 receptor agonist. Tirzepatide is a dual agonist of GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). Both engage the GLP-1 axis and the resulting appetite-suppression and gastric-slowing effects. Tirzepatide adds GIP receptor activity, which the published mechanistic literature has tied to additional effects on adipose tissue, insulin secretion, and possibly fat oxidation. Whether GIP agonism, antagonism, or balanced modulation is the optimal pharmacology is still debated, but the clinical effect is what matters for users.

The direct head-to-head trial

SURPASS-2 was a 40-week randomized trial comparing tirzepatide (5, 10, 15 mg weekly) against semaglutide 1 mg weekly in adults with type 2 diabetes. All tirzepatide doses produced larger HbA1c reductions and larger weight reductions than semaglutide 1 mg. The dose-response was consistent: higher tirzepatide doses produced larger effects .

An important caveat: SURPASS-2 used semaglutide 1 mg, the diabetes label dose. The obesity-specific dose of semaglutide is 2.4 mg weekly (Wegovy). The SURPASS-2 result therefore does not directly answer the question 'tirzepatide 15 mg vs. semaglutide 2.4 mg for weight'.

Side-by-side obesity programs

• STEP-1: semaglutide 2.4 mg weekly for 68 weeks produced ~14.9 percent weight reduction in adults with overweight or obesity .
• SURMOUNT-1: tirzepatide 15 mg weekly for 72 weeks produced ~20.9 percent weight reduction in a similar population .
• Trial designs differ in duration, lifestyle-intervention intensity, and population characteristics; cross-trial comparison is suggestive, not definitive.
• Discontinuation pattern is similar across drugs: weight regain follows discontinuation in both programs.

Tolerability and side effects

GI side effects (nausea, diarrhea, vomiting, constipation) are class-typical for both drugs and most prominent during titration. SURPASS-2 reported broadly similar tolerability profiles, with discontinuation rates due to adverse events in roughly the same range across arms. Cholelithiasis, pancreatitis, and gastroparesis are class warnings that appear in both labels .

Compounded-product cautions

The trial data discussed here come from labeled, FDA-approved products. The compounded versions of semaglutide and tirzepatide do not have equivalent CMC oversight, and the FDA has flagged dosing-error patterns associated with compounded GLP-1 products . Cross-trial comparisons of efficacy do not necessarily transfer to compounded preparations.